In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

GPC AG to buy Mitotix in all-stock deal

Executive Summary

GPC AG (genomics) is buying Mitotix (cell cycle inhibitors) for 30% of GPC's stock The new company will be called GPC Biotech AG, with GPC AG CEO Bernd Seizinger retaining that role at the new firm; Mitotix's Muzammil Mansuri will lead US operations.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Stock

Related Companies